Symbols

PRTK(Delisted)

Paratek Pharmaceuticals·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About PRTK

Paratek Pharmaceuticals, Inc.

A commercial-stage biopharmaceutical company that develops innovative antibacterial therapeutics based upon teracycline chemistry

Industry

Established Date

Listing Date

05/10/2006

Exchange

NASDAQ Stock Exchange

Full-time Employees

268

Fiscal Year Ends

12-31

Website

www.paratekpharma.com

Security Type

Common stock

Office address

75 Park Plaza, Boston, MA 02116

Business

Introduction

Founded in 2001 as Novacea, Paratek Pharmaceuticals, Inc., located in Delaware, is a specialized pharmaceutical company focused on the development and sale of proprietary products that address important therapeutic needs in the field of neuropathy. The company's goal is to become a leading developer and marketer of pharmaceutical products to meet the therapeutic needs in the field of neurology, with the company's initial focus on psychiatry. The Company's partnership with Purdue Pharma gives the Company the potential to develop its own specialized sales and marketing capabilities in the United States, primarily to market Intermezzo products to psychiatric patients and other products developed to address unmet needs in the field of neuropathy. The company's goal is to develop its own sales and promotion infrastructure, and to start business operations that can be further supported by the successful research and development of TO-2061 and the licensing of other products of the company.

Company Financials

EPS

PRTK has released its 2023 Q2 earnings. EPS was reported at -0.25, versus the expected -0.31, beating expectations. The chart below visualizes how PRTK has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

PRTK has released its 2023 Q2 earnings report, with revenue of 39.99M, reflecting a YoY change of 34.94%, and net profit of -14.55M, showing a YoY change of 17.40%. The Sankey diagram below clearly presents PRTK's revenue sources and cost distribution.